BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31317768)

  • 1. Harnessing radiation to improve immunotherapy: better with particles?
    Durante M; Formenti S
    Br J Radiol; 2020 Mar; 93(1107):20190224. PubMed ID: 31317768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Charged particle beams to cure cancer: Strengths and challenges.
    Durante M; Flanz J
    Semin Oncol; 2019 Jun; 46(3):219-225. PubMed ID: 31451308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical applications of proton and carbon ion therapy.
    Rackwitz T; Debus J
    Semin Oncol; 2019 Jun; 46(3):226-232. PubMed ID: 31451309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Particle beam radiotherapy].
    Saitoh J; Nakano T
    Gan To Kagaku Ryoho; 2014 Dec; 41(13):2546-9. PubMed ID: 25596047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are charged particles a good match for combination with immunotherapy? Current knowledge and perspectives.
    Helm A; Totis C; Durante M; Fournier C
    Int Rev Cell Mol Biol; 2023; 376():1-36. PubMed ID: 36997266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heavy charged particle radiobiology: using enhanced biological effectiveness and improved beam focusing to advance cancer therapy.
    Allen C; Borak TB; Tsujii H; Nickoloff JA
    Mutat Res; 2011 Jun; 711(1-2):150-7. PubMed ID: 21376738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable Senescence Induction in Three-dimensional Human Cartilage Model by Exposure to Therapeutic Doses of X-rays or C-ions.
    Hamdi DH; Chevalier F; Groetz JE; Durantel F; Thuret JY; Mann C; Saintigny Y
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):139-146. PubMed ID: 27084635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proceedings of the National Cancer Institute Workshop on Charged Particle Radiobiology.
    Mohan R; Held KD; Story MD; Grosshans D; Capala J
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):816-831. PubMed ID: 29485053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the use of protons and carbon ions for treatment.
    Uhl M; Herfarth K; Debus J
    Cancer J; 2014; 20(6):433-9. PubMed ID: 25415691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of clinical results of charged-particle therapy for esophageal cancer.
    Ono T
    Esophagus; 2021 Jan; 18(1):33-40. PubMed ID: 32654019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.
    Kano M; Matsushita K; Rahmutulla B; Yamada S; Shimada H; Kubo S; Hiwasa T; Matsubara H; Nomura F
    Gene Ther; 2016 Jan; 23(1):50-6. PubMed ID: 26241176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton and Carbon Ion Therapy of Intracranial Gliomas.
    Combs SE
    Prog Neurol Surg; 2018; 32():57-65. PubMed ID: 29990974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluence-based dosimetry of proton and heavier ion beams using single track detectors.
    Klimpki G; Mescher H; Akselrod MS; Jäkel O; Greilich S
    Phys Med Biol; 2016 Feb; 61(3):1021-40. PubMed ID: 26757791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Potentiation of Anti-Tumor Immunity by Tumor Abolition with Alpha Particles, Protons, or Carbon Ion Radiation and Its Enforcement by Combination with Immunoadjuvants or Inhibitors of Immune Suppressor Cells and Checkpoint Molecules.
    Keisari Y; Kelson I
    Cells; 2021 Jan; 10(2):. PubMed ID: 33503958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging issues specific to hadrontherapy (proton, carbon, helium therapy and other charged particles) for radiotherapy planning, setup, dose monitoring and tissue response assessment.
    Thariat J; Hérault J; Beddok A; Feuvret L; Dauvergne D; Gérard M; Balosso J; Noël G; Valable S
    Cancer Radiother; 2020 Aug; 24(5):429-436. PubMed ID: 32247687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions.
    Genet SC; Maeda J; Fujisawa H; Yurkon CR; Fujii Y; Romero AM; Genik PC; Fujimori A; Kitamura H; Kato TA
    Oncol Rep; 2012 Nov; 28(5):1591-6. PubMed ID: 22923057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbon Ion Radiobiology.
    Tinganelli W; Durante M
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33080914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis.
    Makishima H; Ishikawa H; Terunuma T; Hashimoto T; Yamanashi K; Sekiguchi T; Mizumoto M; Okumura T; Sakae T; Sakurai H
    J Radiat Res; 2015 May; 56(3):568-76. PubMed ID: 25755255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct modes of death in human neural stem and glioblastoma cells irradiated with carbon-ion radiation and gamma-rays.
    Yokota Y; Wada Y; Funayama T
    Int J Radiat Biol; 2020 Feb; 96(2):172-178. PubMed ID: 31633435
    [No Abstract]   [Full Text] [Related]  

  • 20. Particle therapy in Europe.
    Grau C; Durante M; Georg D; Langendijk JA; Weber DC
    Mol Oncol; 2020 Jul; 14(7):1492-1499. PubMed ID: 32223048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.